XTX Topco Ltd Purchases Shares of 36,674 OptimizeRx Co. (NASDAQ:OPRX)

XTX Topco Ltd acquired a new stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 36,674 shares of the company's stock, valued at approximately $178,000. XTX Topco Ltd owned 0.20% of OptimizeRx at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in OPRX. Whetstone Capital Advisors LLC acquired a new stake in OptimizeRx during the 4th quarter worth about $6,563,000. Royce & Associates LP purchased a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $5,198,000. Kennedy Capital Management LLC grew its position in OptimizeRx by 57.8% during the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock worth $2,887,000 after purchasing an additional 217,676 shares in the last quarter. JPMorgan Chase & Co. raised its stake in OptimizeRx by 670.3% during the 4th quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company's stock valued at $291,000 after purchasing an additional 52,169 shares during the period. Finally, AMH Equity Ltd lifted its holdings in shares of OptimizeRx by 25.0% in the fourth quarter. AMH Equity Ltd now owns 125,000 shares of the company's stock valued at $608,000 after purchasing an additional 25,000 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on OPRX shares. JMP Securities reaffirmed a "market outperform" rating and set a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. B. Riley raised shares of OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $9.06.

Insider Activity at OptimizeRx

In related news, Director James Paul Lang purchased 321,408 shares of the firm's stock in a transaction on Friday, March 14th. The shares were bought at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the transaction, the director now directly owns 389,452 shares of the company's stock, valued at approximately $2,959,835.20. This trade represents a 472.35 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 6.10% of the company's stock.

OptimizeRx Stock Performance

OPRX traded down $0.06 during midday trading on Wednesday, reaching $9.12. The company's stock had a trading volume of 146,005 shares, compared to its average volume of 266,679. OptimizeRx Co. has a twelve month low of $3.78 and a twelve month high of $14.13. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The stock has a market cap of $168.63 million, a P/E ratio of -6.86 and a beta of 1.18. The company has a fifty day simple moving average of $7.44 and a 200 day simple moving average of $6.12.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.